See more : Trevena, Inc. (TRVN) Income Statement Analysis – Financial Results
Complete financial analysis of Organicell Regenerative Medicine, Inc. (BPSR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Organicell Regenerative Medicine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Daiwa Securities Group Inc. (DSEEY) Income Statement Analysis – Financial Results
- TELESYS SOFTWARE LTD. (TELESYS.BO) Income Statement Analysis – Financial Results
- Self Storage Group ASA (SSG.OL) Income Statement Analysis – Financial Results
- KEYNOTE FINANCIAL SERVICES Limited (KEYFINSER.BO) Income Statement Analysis – Financial Results
- VGP NV (VGPBF) Income Statement Analysis – Financial Results
Organicell Regenerative Medicine, Inc. (BPSR)
About Organicell Regenerative Medicine, Inc.
Organicell Regenerative Medicine, Inc. processes, distributes, and supplies biologically processed cellular and tissue-based products in the United States. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. has an agreement with Regenerative Care Network to study potential therapeutic benefits of Zofin for patients with heart failure. Organicell Regenerative Medicine, Inc. was founded in 2011 and is headquartered in Miami, Florida.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.06M | 1.70M | 964.53K | 569.85K | 184.88K | 147.63K | 49.20K | 82.97K | 87.15K | 18.08K |
| Cost of Revenue | 398.61K | 300.84K | 209.30K | 160.63K | 94.40K | 49.41K | 20.06K | 44.44K | 61.12K | 10.99K |
| Gross Profit | 2.66M | 1.40M | 755.23K | 409.22K | 90.48K | 98.22K | 29.14K | 38.53K | 26.03K | 7.09K |
| Gross Profit Ratio | 86.96% | 82.33% | 78.30% | 71.81% | 48.94% | 66.53% | 59.23% | 46.44% | 29.87% | 39.19% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 15.10M | 3.18M | 4.25M | 9.05M | 0.00 | 861.10K | 94.96K | 70.70K | 38.37K | 18.81K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.10M | 3.18M | 4.25M | 9.05M | 0.00 | 861.10K | 94.96K | 70.70K | 38.37K | 18.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 1.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.10M | 3.18M | 4.25M | 9.05M | 1.13M | 861.10K | 94.96K | 70.70K | 38.37K | 18.81K |
| Cost & Expenses | 15.49M | 3.48M | 4.45M | 9.21M | 1.23M | 910.51K | 115.02K | 115.14K | 99.49K | 29.80K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 177.74K | 46.60K | 228.33K | 576.02K | 12.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 36.78K | 14.79K | 7.84K | 19.32K | 345.00 | 86.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.37M | -1.68M | -3.23M | -8.38M | -1.24M | -738.27K | -65.82K | -32.18K | -12.34K | -11.73K |
| EBITDA Ratio | -404.76% | -98.45% | -334.46% | -1,470.01% | -670.77% | -500.08% | -133.78% | -38.78% | -14.16% | -64.85% |
| Operating Income | -12.44M | -1.78M | -3.49M | -8.64M | -1.04M | -762.88K | -65.82K | -32.18K | -12.34K | -11.73K |
| Operating Income Ratio | -407.03% | -104.36% | -361.85% | -1,516.47% | -564.32% | -516.76% | -133.78% | -38.78% | -14.16% | -64.85% |
| Total Other Income/Expenses | -145.03K | 38.19K | 58.69K | -471.00K | -12.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -12.58M | -1.74M | -3.43M | -9.11M | -1.06M | -762.88K | -65.82K | -32.18K | -12.34K | -11.73K |
| Income Before Tax Ratio | -411.78% | -102.12% | -355.76% | -1,599.12% | -571.20% | -516.76% | -133.78% | -38.78% | -14.16% | -64.85% |
| Income Tax Expense | 32.72K | 84.79K | 287.02K | 105.02K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -12.58M | -1.74M | -3.46M | -8.97M | -1.25M | -738.35K | -65.82K | -32.18K | -12.34K | -11.73K |
| Net Income Ratio | -411.78% | -102.06% | -358.95% | -1,574.49% | -677.84% | -500.14% | -133.78% | -38.78% | -14.16% | -64.85% |
| EPS | -0.02 | -0.01 | -0.01 | -0.08 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | -0.08 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 670.82M | 271.81M | 271.81M | 108.60M | 100.38M | 150.12M | 150.12M | 143.45M | 135.00M | 1.04B |
| Weighted Avg Shares Out (Dil) | 670.82M | 271.81M | 271.81M | 108.60M | 100.38M | 150.12M | 150.12M | 143.45M | 135.00M | 1.04B |
Organicell Launches Autologous Blood Derived Platform PPX™ – Patient Pure X™
MIAMI--(BUSINESS WIRE)---- $BPSR #biotech--Organicell launches a service platform for their first autologous product called Patient Pure X (PPX).
Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan
MIAMI--(BUSINESS WIRE)---- $BPSR #biotech--Organicell signs an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin to hospitals and clinics.
Organicell and The Centers for Disease Control and Prevention Enter Into Agreement To Conduct Research on Influenza Viruses of Pandemic Potential
MIAMI--(BUSINESS WIRE)---- $BPSR #biotech--Organicell and the CDC agree to use Zofin in experimental research for influenza.
‘Frontiers in Medicine' Publishes Organicell's Case Report Demonstrating the Use of Zofin™ in the Treatment of COVID-19 Patients
MIAMI--(BUSINESS WIRE)---- $BPSR #biotech--Organicell announces the publication of a peer-reviewed case report analyzing the clinical outcomes of Zofin treatment in COVID-19 patients.
Organicell Announces FDA Approval of IND Application for the Use of Zofin™ in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
MIAMI--(BUSINESS WIRE)---- $BPSR #COPD--Organicell announces FDA approval of IND application for the use of its lead product, Zofin in treating chronic obstructive pulmonary disease (COPD).
The Forgotten Ones. Will Long-Haulers Be the Next Public Health Crisis?
MIAMI BEACH, Fla.--(BUSINESS WIRE)---- $BPSR #Zofin--Organicell will host a live online discussion on COVID-19 long-haulers.
Source: https://incomestatements.info
Category: Stock Reports